Correction: Corrigendum: Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing

Lisa R. Susswein MS, MHA, Megan L. Marshall MS, Rachel Nusbaum MS, Kristen J. Vogel Postula MS, Scott M. Weissman MS, Lauren Yackowski MS, Erica M. Vaccari MS, Jeffrey Bissonnette MSc, Jessica K. Booker PhD, M. Laura Cremona PhD, Federica Gibellini PhD, Patricia D. Murphy PhD, Daniel E. Pineda-Alvarez MD, Guido D. Pollevick PhD, Zhixiong Xu PhD, Gabi Richard MD, Sherri Bale PhD, Rachel T. Klein MS, Kathleen S. Hruska PhD and Wendy K. Chung MD, PhD

Genet Med advance online publication, December 17, 2015; doi:10.1038/gim.2015.166

In the published version of this article, there was an error in Supplementary Table 2. The premature termination number for gene CDKN2A should be 0, not 2. The corrected table appears in the online version of this corrigendum.

In addition, there were a number of errors in Table 3. The total of variants identified in the 89 women with ovarian cancer with no reported previous BRCA1/2 genetic testing should have been 92, not 91. The yield figure and gene counts are correct in the paper, but the discrepancy slightly affects the proportion of pathogenic/likely pathogenic variants identified in each gene category. The corrected proportions would be: BRCA1/2 (46/92, 50.0%), Lynch (14/92, 15.2%), Other High Risk (2/92, 2.2%), Moderate or Unknown Risk (30/92, 32.6%). For endometrial cancer, the statistics should be as follows. There were 53, not 54, positive women, for a yield of 11.7% (53/453). There were a total of 56, not 55, pathogenic and likely pathogenic variants among the 53 positive women. The gene categories were as follows: BRCA1/2 (6/56, 10.7%); Lynch (33/56, 58.9%), Other High Risk (4/56, 7.1%), Moderate or Unknown Risk genes (13/56, 23.2%). The breakdown of total pathogenic and likely pathogenic (likely pathogenic in parentheses) results by gene was: BRCA1 2, BRCA2 4, MSH6 16, MSH2 8, MLH1 6, PMS2 3, MUTYH 4, CHEK2 7(3), ATM 2(1), BRIP1 1, FANCC 1, PALB2 1, RAD51C 1. The correct table appears below.

Table 3.

Yields by cancer type and genes with pathogenic (P) and likely pathogenic (LP) variants among patients with specific clinical histories

The authors regret these errors.